trial

A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

NCTId NCT02088060
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 150 (estimated)
Sponsored by Central Institute of Mental Health, Mannheim
Primary completion 2024-09-16
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
150 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2015-12-08
Primary completion
2024-09-16
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
CannabidiolOlanzapine

Sponsors

Central Institute of Mental Health, MannheimLead Sponsor
Martin-Luther-Universität Halle-WittenbergCollaborator
Heidelberg UniversityCollaborator
Technical University of MunichCollaborator
Ludwig-Maximilians - University of MunichCollaborator
Glostrup University Hospital, CopenhagenCollaborator

Investigators

1
F. Markus Leweke, MDPrincipal Investigator

Sites

6 total
Glostrup Municipality, DenmarkHeidelberg, GermanyMannheim, GermanyMunich, GermanyMunich, GermanyHalle, Germany

Linked catalysts

1
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a — primary completion2024-09-16

Facts & assertions

4 sourced
Enrollment
150
Phase
PHASE2
Primary Completion Date
2024-09-16
Status
TERMINATED
relationships
The graph out of here
drug
Cannabidiol
drug
Olanzapine
drug
lead_sponsor
Central Institute of Mental Health, Mannheim
company
collaborator
Martin-Luther-Universität Halle-Wittenberg
company
Heidelberg University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
F. Markus Leweke, MD
person